Evaluation of Tracer Kinetic Models for Analysis of [18F]FDDNP Studies by Yaqub, Maqsood et al.
B The Author(s), 2009
Published Online: 2 April 2009 DOI: 10.1007/s11307-009-0208-1
Mol Imaging Biol (2009) 11:322Y333
RESEARCH ARTICLE
Evaluation of Tracer Kinetic Models for Analysis
of [
18F]FDDNP Studies
Maqsood Yaqub,
1 Ronald Boellaard,
1 Bart N. M. van Berckel,
1 Nelleke Tolboom,
2
Gert Luurtsema,
1 Anke A. Dijkstra,
1 Mark Lubberink,
1 Albert D. Windhorst,
1
Philip Scheltens,
2 Adriaan A. Lammertsma
1
1Department of Nuclear Medicine & PET Research, VU University Medical Centre, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands
2Department of Neurology & Alzheimer Centre, VU University Medical Centre, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands
Abstract
Purpose: Different pharmacokinetic methods for [
18F]FDDNP studies were evaluated using both
simulations and clinical data.
Procedures: Methods included two-tissue reversible plasma (2T4k), simplified reference tissue
input (SRTM), and a modified 2T4k models. The latter included an additional compartment for
metabolites (2T1M). For plasma input models, binding potential, BPND, was obtained both
directly (=k3/k4) and indirectly (using volume of distribution ratios).
Results: For clinical data, 2T1M was preferred over 2T4k according to Akaike criterion. Indirect
BPND using 2T1M correlated better with SRTM then direct BPND. Fairly constant volume of
distribution of metabolites was found across brain and across subjects, which was strongly
related to bias in BPND obtained from SRTM as seen in simulations. Furthermore, in simulations,
SRTM showed constant bias with best precision if metabolites entered brain.
Conclusions: SRTM is the method of choice for quantitative analysis of [
18F]FDDNP even if it is
unclear whether labeled metabolites enter the brain.
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Introduction
[
18F]
FDDNP has recently been introduced [1]a sa
positron emission tomography (PET) ligand for
in vivo imaging of amyloid plaques and neurofibrillary
tangles in the human brain. Plaques and tangles are thought
to be the hallmark of Alzheimer’s disease (AD) [2], and
early in vivo detection of these neuropathological lesions
could be an important step in evaluating future treatment
strategies for AD.
So far, only a few methods for quantification of [
18F]
FDDNP have been evaluated, such as residence time within a
cerebral region relative to that in pons [3], standardized uptake
value (SUV) [4], distribution volume ratio (DVR) [4] obtained
with Logan analysis [5] using cerebellum as reference region,
and several simplified reference tissue-based methods [6]a l s o
using cerebellum as reference region. Using Logan analysis,
Kepe et al. [7] recently reported increased levels of [
18F]
FDDNP binding in neocortical regions compared with that in
cerebellum in AD patients, whereas no difference in uptake
between cerebellum and other regions was found in healthy
controls (HC). In addition, Small et al. [8] found that global
DVR values in HC were lower than in patients with mild
cognitive impairment (MCI), which in turn were lower than in
ADsubjects.However,arterialsamplingwasnotusedinanyof
these studies. Arterial sampling is considered to be the gold
standard, especially if pathological changes may also affect
reference regions.
The purpose of the present study was to investigate which
pharmacokinetic model could best be used for quantitative Correspondence to: Maqsood Yaqub; e-mail: Maqsood.Yaqub@VUmc.nlanalysis of [
18F]FDDNP studies. To this end, both simulated
and clinical [
18F]FDDNP data were used. Data were
analyzed using various compartmental models based on
plasma [9] and reference tissue [10–12] input data. In
addition, a plasma input model was evaluated, which
accounted for uptake of labeled metabolites in the brain.
Finally, standard uptake value ratios with cerebellum (SUVr)
were investigated.
Methods
Scanning Protocol
Clinical data were derived from ongoing patient studies consisting
of 12 subjects (six HC, three MCI [13], and three AD) with ages
ranging from 58 to 72 years. Mean age (±SD) was 66±5, 68±4,
and 63±6 for HC, MCI, and AD, respectively. AD patients were
diagnosed with probable AD meeting NINCDS-ADRDA criteria
[14]. The study was approved by the Medical Ethics Committee of
the VU University Medical Centre, and each subject gave written
informed consent prior to inclusion in the study. Clinical results are
beyond the scope of the present study and will be reported
elsewhere.
As part of the study protocol, each subject first underwent a T1-
weighted magnetic resonance imaging (MRI) scan using a 1.5-T
SONATA scanner (Siemens Medical Solutions, Erlangen, Ger-
many). This MRI scan was performed to exclude anatomical
abnormalities and for co-registration and segmentation purposes.
PET studies were performed using an ECAT EXACT HR+
scanner (CTI/Siemens, Knoxville, USA). The characteristics of this
scanner have been described previously [15]. First, a 10-min
transmission scan in 2D acquisition mode was performed. This scan
was used to correct the subsequent emission scan for tissue
attenuation. Next, a dynamic emission scan in 3D acquisition mode
was performed following bolus injection of 168±8 MBq [
18F]
FDDNP [16]. This dynamic emission scan consisted of 23 frames
(1×15, 3×5, 3×10, 2×30, 3×60, 2×150, 2×300, 7×600 s) with a
total scan duration of 90 min. All frames were reconstructed using
FORE+ 2D filtered back projection [17] and a Hanning filter with a
cutoff of 0.5 times the Nyquist frequency. Reconstructions included
all standard corrections, such as normalization, and decay, dead
time, attenuation, randoms, and scatter [18] corrections.
The protocol also included continuous arterial sampling, starting
2 min prior to injection and continuing up to 60 min, using a
dedicated online detection system [19]. In addition, at set times (5,
10, 20, 40, and 60 min post-injection), arterial sampling was
interrupted briefly for the withdrawal of discrete arterial samples.
After each sample, the arterial line was flushed with heparinized
saline in order to avoid clotting within the line. Finally, two manual
samples were withdrawn at 75 and 90 min post-injection.
Arterial blood samples were used to determine plasma and
whole blood radioactivity concentrations using a well counter cross
calibrated against the PET scanner [20]. In addition, plasma parent
tracer and metabolite concentrations were determined using solid
phase extraction combined with high-performance liquid chroma-
tography technology and equipped with off-line radioactivity
detection [21]. An arterial whole blood curve was obtained by
correcting the online sampler curve for decay, removing the
flushing periods, and calibrating against the discrete (whole blood)
sample data. Finally, a metabolite-corrected plasma curve was
derived from this whole blood curve using both plasma to whole
blood ratios and metabolite fractions obtained from the manual
blood samples. To this end, the total fraction of labeled metabolites
as function of time was fitted to a Hill-type function [22]. This
function provided more accurate fits than other functions such as
multi-exponentials. Arterial blood sampling was not available for
six subjects (three HC and three MCI). Data from these subjects
were only used for investigating reference tissue models.
Image Analysis
De-skulled T1-weighted MRI scans [23] were co-registered [24, 25]
with a summed PET image (frames 3–12, 25 s–5 min post-injection).
This summed PET image resembles a flow image, thereby
maximizing cortical information. Time– activity curves were then
generated using MR-based automatic delineation of regions of
interest (ROI), as described by Svarer et al. [26]. For the purpose
of the present study, only TACs from 17 regions (cerebellum, orbital
frontal cortex, medial inferior frontal cortex, anterior cingulate
cortex, thalamus, insula, caudate, putamen, superior temporal cortex,
parietal cortex, medial inferior temporal cortex, superior frontal
cortex, occipital cortex, sensory motor cortex, posterior cingulate
cortex, enthorinal cortex, hippocampus), all averaged over left and
right hemispheres, were analyzed. These anatomical regions were
small and defined in gray matter only, thereby minimizing signal
dilution due to partial volume effects as much as possible.
Kinetic Analyses of Clinical Data
Clinical data were analyzed using conventional plasma input and
reference tissue-based algorithms [9]. As there is some concern that
labeled [
18F]FDDNP metabolites might cross the blood–brain
barrier [27, 28], additional analyses were performed using a plasma
input model accounting for metabolites entering the brain. In
addition, average regional activity concentration ratios with the
reference region (SUVr) were derived over the time intervals of 40–
60, 60–90, and 80–90 min after injection. For all reference tissue
models and SUVr cerebellar gray matter was used as reference
region based on its relatively low levels of amyloid and
neurofibrillary tangles [2].
Five different conventional compartmental models were evalu-
ated: single-tissue (1T2k), two-tissue irreversible (2T3k) and two-
tissue reversible (2T4k) plasma input models, and simplified
(SRTM) [12] and full (FRTM) [10, 11] reference tissue models.
Plasma input models contained one additional fit parameter for
blood volume. The SRTM was used to estimate binding potential
directly BPSRTM
ND

. The 2T4k plasma input model was used to
estimate binding potential both directly BP2T4k
ND ¼

k3=k4Þ and
indirectly using volume of distribution ratios BP2T4k i
ND ¼

DVR   1 ¼ V
target
T

gVcerebellum
T   1Þ [11]. The latter ap-
proach will be indicated by 2T4k
i.
Based on the possibility of metabolites entering the brain [27,
28], also a modified 2T4k model was used. This model
included an additional (parallel) single-tissue compartment for
labeled metabolites (2T1M, Fig. 1). The metabolite input curve
was based only on polar metabolites and ignores the minor
fraction of other metabolites. The direct binding potential
BP2T1M
ND for this model was defined as k3/k4 (Fig. 1), and the
volumes of distributions, VT and VTm, were defined as
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
k2   1 þ BP2T1M
ND

and K1m/k2m, respectively. Similar to
2T4k
i, the binding potential was also estimated indirectly using
the volume of distribution ratios with the cerebellum as reference
region BP2T1Mi
ND

. All 2T1M fits were repeated after fixing VTm
to the cerebellum value (=2T1Mfvtm). This model was also used to
estimate binding potential both directly BP2T1M fvtm
ND

and
indirectly using DVR−1 ¼ BP2T1M i fvtm
ND

. The indirect meth-
ods for estimating BPND using 2T1M and 2T1Mfvtm will be
indicated by 2T1M
i and 2T1Mi
fvtm,r e s p e c t i v e l y .
Clinical Studies
Clinical results were evaluated in several ways. First, for all
compartmental models (SRTM, FRTM, 1T2k, 2T3k, 2T4k, 2T1M,
and 2T1Mfvtm), fitted TACs were evaluated using the Akaike
criterion. Next, where possible, BPND values were estimated both
directly and indirectly using VT ratios with cerebellum (i.e., 2T4k
i,
2T1M
i and 2T1Mi
fvtm). In addition, estimates of BPND were
compared with BPSRTM
ND . Finally, SUVr−1 values were estimated
and compared with BPSRTM
ND , given that at true equilibrium, SUVr
corresponds with DVR.
Simulation Studies
Conventional Simulations Simulated time–activity curves
(TACs) for target and reference regions were generated using a
typical [
18F]FDDNP plasma input function in combination with the
two-tissue reversible plasma input model (2T4k). In the simula-
tions, variations in binding, delivery, and fractional blood volume
were investigated.
Kinetic parameters were based on typical 2T4k parameters
obtained from clinical data. Default parameters for simulated
reference and target tissue TACs are given by R1 and T1,
respectively, as listed in Table 1. Target tissue parameters were
varied with respect to binding potential (BP2T4k
ND and BP2T4k i
ND :
T2–T5), fractional blood volume (Vb: T6, T7), and delivery (K1:
T8–T15). One hundred TACs were generated for each run and
noise was added to simulate an average noise level of 7.5%
coefficient of variation (COV). Noise simulation was based on
clinically derived typical values of total scanner true counts, frame
lengths, and decay correction factors. A detailed description of the
noise simulation used is given in [29].
Simulated data were analyzed using conventional models as
described above (1T2k, 2T3k, 2T4k, SRTM, FRTM, and 2T4k
i)
and SUVr methods over the time intervals 40–60, 60–90, and 80–
90 min. Fits were evaluated by comparing goodness of fit
according to the Akaike criterion. Next, models were evaluated
by comparing bias and COV of estimated binding potential (where
appropriate, also the indirect estimation through volumes of
distribution). Bias was estimated in relative terms using
100   BPmodel
ND =

BPsimulated
ND   1Þ, where BPmodel
ND represents
BPND estimated using the method of analysis under investigation
and BPsimulated
ND simulated BPND, which was set to either BP2T4k
ND
or BP2T4k i
ND for direct and indirect methods, respectively.
Metabolite Model To simulate the effects of cerebral uptake of
labeled metabolites, simulated TACs were generated using a typical
[
18F]FDDNP plasma input function in combination with the 2T1M
model. Kinetic parameters were based on typical 2T1M parameters
obtained from clinical data. Default parameters for simulated
reference and target tissue TACs are given by R1 and T1,
respectively, as listed in Table 2. Target tissue parameters were
varied, including binding potential (BP2T1M
ND and BP2T1M i
ND :T 2 –
Fig. 1. Schematic diagram of the model that includes a tissue
metabolite compartment. BBB represents the blood–brain
barrier; P
Parent and P
Met are tracer plasma radioactivity concen-
trations (Bq ml
−1) of parent and labeled metabolites, respec-
tively; T is the radioactivity concentration in tissue,
F+NS
Parent that of free and non-specifically bound parent in
tissue, S
Parent that of bound parent in tissue; and F+NS
Met that
of labeled metabolites in tissue (Bq ml
−1); K1 (ml·cm
−3·min
−1)
and k2 (min
−1) are rate constants, describing exchange of
parent between plasma and tissue; k3 and k4 are rate
constants (min
−1), describing exchange of parent between
free and bound compartments; K1m (ml·cm
−3·min
−1)a n dk2m
(min
−1) are rate constants, describing exchange of labeled
metabolites between plasma and tissue.
Table 1. Kinetic parameters used to generate reference (R) and target (T)
tissue time activity curves (TAC)
TAC K1 (ml·cm
−3·min
−1) BP2T4k
ND
Vb VT BP2T4k i
ND
R 1 0.35 1.63 0.050 8.7 –
T 1 0.35 2.3 0.050 11 0.25
T 2 0.35 1.7 0.050 8.9 0.03
T 3 0.35 2.0 0.050 9.9 0.14
T 4 0.35 2.6 0.050 12 0.37
T 5 0.35 2.9 0.050 13 0.48
T 6 0.35 2.3 0.025 11 0.25
T 7 0.35 2.3 0.075 11 0.25
T 8 0.21 2.3 0.050 11 0.25
T 9 0.25 2.3 0.050 11 0.25
T 10 0.28 2.3 0.050 11 0.25
T 11 0.32 2.3 0.050 11 0.25
T 12 0.39 2.3 0.050 11 0.25
T 13 0.43 2.3 0.050 11 0.25
T 14 0.46 2.3 0.050 11 0.25
T 15 0.50 2.3 0.050 11 0.25
K1, k2, and k3 are rate constants, Vb is fractional blood volume, VT is volume
of distribution, and BP2T4k
ND and BP2T4k i
ND are binding potentials
estimated directly (2T4k) and indirectly (2T4k
i) using the reversible two-
tissue model, respectively. The indirect calculation of BPND was performed
using target to reference volumes of distribution ratios. During all
simulations, k4 (0.032 min
−1) and K1/k2 (3.3) were fixed
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distribution of metabolites (VTm: T14–T21). One hundred TACs
were generated for each run and noise was added to simulate an
average noise level of 7.5% COV, as described above.
Simulated data were analyzed using 2T4k, 2T4k
i, 2T1Mfvtm (i.e.,
2T1M with VTm fixed to the simulated value), 2T1Mi
fvtm (i.e.,
indirect estimation through volumes of distribution), and SRTM.
Bias and COV of binding potential obtained were compared between
the various models. Bias for direct and indirect 2T1M models was
defined in a similar way as for the standard models, i.e., using
100   BPmodel
ND =

BPsimulated
ND   1Þ, where BPmodel
ND represents
BPND estimated using the method of analysis under investigation and
BPsimulated
ND simulated BPND, set to either BP2T1M
ND or BP2T1M i
ND for
direct and indirect models, respectively.
In addition to BPND, in metabolite simulations, also VT values
were estimated using 2T4k and the 2T1Mfvtm models. Bias in
estimated VT for the 2T4k model was defined as 100   Vmodel
T
 
Vtotal simulated
T   1Þ, where Vtotal simulated
T is K1=k2 ðÞ   1þ ð
BPNDÞþ K1m=k2m ðÞ . Bias in estimated VT for the 2T1Mfvtm
model was defined as 100   Vmodel
T =

Vsimulated
T   1Þ, where
Vsimulated
T is (K1/k2)×(1+BPND).
Results
Time–Activity Curves
Typical parent [
18F]FDDNP and polar metabolite plasma
curves are shown in Fig. 2a and typical time–activity curves
for cerebellum and frontal cortex in Fig. 2b. The average
(N=5) fractions of [
18F]-labeled metabolites in plasma as
function of time are shown in Fig. 3, fitted using a Hill type
function. Very rapid metabolism of [
18F]FDDNP can be
seen, with metabolite-related [
18F] activity primarily due to
polar metabolites (Fig. 3). The polar metabolites are
composed of N-dealkylated fragments with similar chroma-
togram retention times as primarily fluoroethanal and with a
smaller fractions of fluoroacetic acids [28].
Clinical Studies
Fig. 4 show typical fits using various compartmental models.
In general, poor fits were seen for the 1T2k model (Fig. 4a).
Metabolite models showed slightly better fits (Fig. 4b) than
all conventional models (Fig. 4a). Good fits were seen for
the reference tissue models (Fig. 4c). Similarly, the Akaike
criterion gave preference to 2T1M models above other
plasma input models (2T1Mfvtm 37.3%, 2T1M 31.7%, 2T4k
26.2%, 2T3k 4.8%, and 1T2k 0% preference, respectively).
With respect to reference tissue models, the Akaike criterion
had strong preference for SRTM (88%).
Average values of the various parameters, together with
observed range, for 2T4k, 2T1M, and SRTM models are
given in Tables 3, 4, and 5 for typical AD regions, i.e., for
regions previously shown to be involved in AD [8]. These
regions were used in order to accurately estimate typical
kinetic parameters for AD subjects, as the latter parameter
estimates were used in the simulations.
Fig. 5 shows high correlation (R
2=0.95) between K1m
and k2m values from the 2T1M model over all regions and
subjects, indicating an almost constant VT for metabolites.
Table 6 shows correlation coefficients obtained from linear
regression analyses of various outcome measures with
Table 2. Kinetic parameters used to generate reference (R) and target (T) TAC
TAC K1 (ml·cm
−3·min
−1) BP2T1M
ND
Vb VT BP2T1M i
ND
K1m (ml·cm
−3·min
−1) VTm
R 1 0.34 0.65 0.05 4 –– –
T 1 0.34 1.3 0.05 5.59 0.39 0.50 0.59
T 2 0.34 0.8 0.05 4.37 0.09 0.50 0.6
T 3 0.34 1.0 0.05 4.86 0.21 0.50 0.6
T 4 0.34 1.2 0.05 5.34 0.33 0.50 0.6
T 5 0.34 1.4 0.05 5.83 0.45 0.50 0.6
T 6 0.34 1.6 0.05 6.31 0.58 0.50 0.6
T 7 0.34 1.8 0.05 6.80 0.70 0.50 0.6
T 8 0.34 2.1 0.05 7.53 0.88 0.50 0.6
T 9 0.34 2.3 0.05 8.01 1.00 0.50 0.6
T 10 0.34 1.3 0.05 5.59 0.39 0.00 0.6
T 11 0.34 1.3 0.05 5.59 0.39 0.01 0.6
T 12 0.34 1.3 0.05 5.59 0.39 0.03 0.6
T 13 0.34 1.3 0.05 5.59 0.39 0.05 0.6
T 14 0.34 1.3 0.05 5.59 0.39 0.50 0.1
T 15 0.34 1.3 0.05 5.59 0.39 0.50 0.2
T 16 0.34 1.3 0.05 5.59 0.39 0.50 0.3
T 17 0.34 1.3 0.05 5.59 0.39 0.50 0.4
T 18 0.34 1.3 0.05 5.59 0.39 0.50 0.5
T 19 0.34 1.3 0.05 5.59 0.39 0.50 0.7
T 20 0.34 1.3 0.05 5.59 0.39 0.50 0.8
T 21 0.34 1.3 0.05 5.59 0.39 0.50 0.9
A two-tissue reversible compartmental model with an additional single-tissue compartment for metabolites was used. K1, k2, and k3 are rate constants, Vb is
fractional blood volume, and VT is volume of distribution for [
18F]FDDNP. BP2T1M
ND and BP2T1M i
ND and are binding potentials estimated directly and
indirectly using the metabolite model, respectively. The indirect calculation of BPND was performed using target to reference volumes of distribution ratios.
K1m is a rate constant and VTm the volume of distribution for the metabolites. During all simulations, k4 (0.099 min
−1) and K1/k2 (2.4) were fixed, and same,
the K1m and k2m were used in reference and target tissues
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ND . As expected, high correlation was found between
BPND estimates of SRTM and FRTM (R
2=0.99). In
addition, good correlation was obtained for SUVr over 40–
60 min (R
2=0.93). Note that the 2T1M
i models, i.e.,
including a compartment for metabolites entering the brain,
correlated better with SRTM than the conventional 2T4k
i
model (Table 6 and Fig. 6).
Simulation Studies
Conventional Simulations In general, SRTM produced
better fits than FRTM according to the Akaike criterion
(∼85% preference). According to the same criterion, 2T4k
showed better fits than both 1T2k and 2T3k in all
simulations (∼96% preference). At lower K1 values, howev-
er, preference for 2T4k reduced in favor of 2T3k (max. 33%
preference for 2T3k). Visual inspection showed poor fits for
the 1T2k model, similar to what was seen in clinical fits, and
therefore, it was excluded from further evaluation.
When simulating different levels of binding the 2T4k
model (direct estimation of BPND) showed good overall
accuracy (5% bias BPND), but mediocre precision (24%
COV BPND). Results for reference tissue-based models,
including SUVr, are summarized in Table 7. In general, all
reference tissue-based methods showed increased bias at
lower levels of binding, but results were more stable at
higher levels. Therefore, bias estimates were averaged only
over the stable part, i.e., for BP2T4k i
ND > 0:14. In contrast,
absolute differences with simulated BP2T4k i
ND values were
more stable and are shown over the full range of simulated
BP2T4k i
ND values (Table 7). Average bias (Table 7) over the
stable range of BP2T4k i
ND > 0:14 ðÞ was lowest for indirect
2T4k (2T4k
i). 2T4k
i and SRTM both showed relatively
constant bias and high precision for higher simulated BPND
levels. Finally, best accuracy and precision for SUVr was
obtained with SUVr40–60.
All models were less sensitive to changes in Vb. At a fixed
level of binding (BPND=2.3, BP2T4k i
ND ¼ 0:25), variations in
Fig. 2. Typical [
18F]FDDNP decay corrected time activity
curves from an AD subject for a metabolite-corrected parent
compound and polar metabolites in plasma and b cerebellum
and frontal cortex (ctx) gray matter.
Fig. 3. Fraction of [
18F]-labeled polar metabolites (dark
dashed line) and parent compound (dark line) in plasma as
function of time, averaged over seven subjects, together with
standard deviations (dashed light gray lines at one SD from
average).
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18F]FDDNP Studiesderived BPND due to changes in simulated Vb were smaller
than 5% for all compartmental models. For SUVr methods,
bias (±COV) in approximated BPND (i.e., SUVr−1) depended
on the actual time interval used and changed from 21±16% to
10±18%, from 30±22% to 28±21%, and from 31±41% to
34±45% for SUVr40–60,S U V r60–90, and SUVr80–90,r e s p e c -
tively, when varying Vb of the target region from 0.025 to
0.075.
Delivery differences affected all compartmental methods,
including plasma input models. For the direct 2T4k model,
bias in BPND varied from 10% to −2% when varying K1 of
the target region from 0.212 to 0.496. Results for indirect
2T4k and SRTM are shown in Fig. 7. Results from FRTM are
not included, as BPND bias was as high as 250%. Bias in
BPND (±COV), based on SUVr−1, ranged from −27±18% to
3±17%, from 25±20% to −3±18%, and from 48±36% to −7
±39%forSUVr40–60,S U V r60–90,a n dS U V r80–90,r e s p e c t i v e l y ,
when varying K1 of the target region from 0.212 to 0.496.
Metabolite Simulations Metabolite simulations were limit-
ed to 2T4k, 2T1Mfvtm, and SRTM. SRTM provided the most
precise estimation of BPND over the range of simulated K1m
with a COV of 4.0±0.4%. Although there was a strong
negative bias (−42±7%) for SRTM, it was very constant
Fig. 4. Decay corrected frontal cortex gray matter time–activity curve from an AD subject (=data) with fits using a conventional
plasma input, b metabolite, and c reference tissue models.
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18F]FDDNP Studies(Fig. 8a). 2T1Mi
fvtm provided a more accurate estimate of
BPND (5±7% bias), but precision (COV of 37±20%) was
much poorer than for SRTM (Fig. 8a). 2T1Mfvtm, 2T4k, and
2T4k
i provided lower precision and higher bias in estimated
BPND over the range of simulated K1m (Fig. 8a, b).
However, VT estimates with the 2T1Mfvtm model were much
more accurate and had higher precision (Fig. 8c).
Simulations over a range of different binding levels showed
strong negative bias (−46±4% with COV of 7±6%) for
SRTM, but again, resulting BPND estimates were the most
stable amongst all models tested (Fig. 9a). Similarly, most
accurate results were obtained with indirect 2T1Mfvtm
(Fig. 9a). Precision of both SRTM and 2T1Mi
fvtm improved
with increasing BPND.B P ND estimates obtained with
2T1Mfvtm, 2T4k, and 2T4k
i were not precise and strongly
biased (Fig. 9). Finally, Fig. 10a shows nearly linearly
increasing (negative) bias in BPND obtained with SRTM for
increasing VTm.I nc o n t r a s t ,F i g .10b illustrates that this bias
was independent of K1m for K1m90.1.
Discussion
Clinical Studies
Due to rapid plasma clearance and metabolism [
18F]FDDNP
scans, it proved to be difficult to obtain reliable measure-
ments of metabolite fractions at later time points. As a result,
only incomplete plasma data were available for six of the
subjects, and data from these subjects were only used for
evaluation of reference tissue models. Although only six
subjects with complete plasma input data remained, this
Table 5. Average (±SD) values of the kinetic parameters, together with
their range given between brackets, for the simplified reference tissue
model, derived from clinical data
Data R1 k2 BPSRTM
ND
HC ctx 0.89±0.06 (0.7–1.0) 0.08±0.02 (0.03–0.11) 0.06±0.04 (−0.07–0.12)
AD ctx 0.87±0.08 (0.7–1.0) 0.06±0.02 (0.03–0.11) 0.07±0.04 (0.00–0.14)
BPSRTM
ND is the binding potential estimated using the simplified reference
tissue model
Fig. 5. Correlation between metabolite influx (K1m)a n d
efflux (k2m) rate constants for clinical [
18F]FDDNP data from
several regions of interests and subjects. These rate con-
stants were obtained using a modified two-tissue reversible
model, including an additional single-tissue compartment for
metabolites.
Fig. 6. Correlation of BPND from 2T1M
i
fvtm and 2T4k
i,
respectively, with BPSRTM
ND for clinical [
18F]FDDNP data
obtained from several regions of interest and subjects. 2T4k
i
represents the reversible two-tissue plasma input model and
2T1M
i
fvtm the modified reversible two-tissue model, which
includes an additional parallel single-tissue compartment for
metabolites. For both models, BPND was estimated indirectly
through calculation of distribution volume ratios.
Table 6. Outcome parameters (slope, intercept, and Pearson product
moment correlation coefficient R
2) for linear regression of different models
versus BPSRTM
ND
Model Slope Intercept R
2
FRTM 0.97 0.01 0.99
2T4k −4.11 2.21 0.15
2T4k
i NA
a NA NA
2T1M NA NA NA
2T1M
i 2.66 −0.11 0.68
2T1Mfvtm NA NA NA
2T1Mi
fvtm
2.59 −0.09 0.58
SUVr40–60 1.14 0.03 0.93
SUVr60–90 0.64 0.06 0.69
SUVr80–90 0.46 0.06 0.43
In the case of SUVr methods, SUVr−1 was taken as an estimate of BPND
aNA indicates poor correlation, i.e., R
2G0.10
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tive (plasma input) models. Clearly, however, the difficulties
in obtaining reliable plasma metabolite data should be taken
into account when selecting a method for routine clinical
studies.
Clinical [
18F]FDDNP data were analyzed using conven-
tional models, models correcting for possible metabolites
entering the brain, and activity ratios. Clearly, due to the very
nature of clinical data, absolute statements about accuracy and
precision cannot be given. Therefore, the various methods
were compared using the Akaike criterion. In addition,
resulting BPND values were compared with SRTM, as this
model showed stable results during simulations.
On the basis of the Akaike criterion, plasma input
models with a compartment for metabolites were preferred
over conventional plasma input models, and SRTM was
preferred over FRTM. Good correlations with SRTM were
obtained only for FRTM, SUVr40–60, and plasma input
models that included a compartment for metabolites
entering the brain, such as 2T1M
i and 2T1M
i
fvtm (Fig. 6).
Table 7. Average bias and absolute difference (diff.) with simulated BPND
over a range of simulated BP2T4k i
ND for various reference tissue models
Model Bias (%) SD in bias (%) Diff. SD in diff.
2T4k
i 1 17 0.041 0.033
SRTM −12 16 0.053 0.062
FRTM −13 23 0.094 0.175
SUVr40–60 −1 14 0.034 0.026
SUVr60–90 16 15 0.054 0.037
SUVr80–90 22 33 0.095 0.072
In addition, corresponding SD are given. In the case of SUVr methods,
SUVr−1 was taken as an estimate of BPND. For bias, the range was set from
0.25 to 0.48 due to the large relative biases at lower specific binding. For
absolute difference, the range was set from 0.03 to 0.48
Fig. 7. Bias of BPND for different compartment models for
simulated [
18F]FDDNP data (obtained using 2T4k) as function
of variable target influx rates (K1 target). Error bars represent
SD in bias. K1 in reference region was fixed to 0.35, and K1/k2
was fixed to 3.3 for both target and reference regions. 2T4k
i
and SRTM represent indirect (using volumes of distribution)
two-tissue reversible and simplified reference tissue models,
respectively.
Fig. 8. Bias of a indirect and reference tissue model BPND, b
direct BPND, and c VT estimates from different compartment
models. Error bars represent SD in bias. Simulated [
18F]
FDDNP data were generated using the metabolite plasma
input model (2T1M) with variable metabolite influx rates (K1m).
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18F]FDDNP StudiesFor most other methods, correlations with SRTM were
poor (R
2G0.1).
Specifically, in the case of the metabolite models,
somewhat large values were seen for the micro parameters
K1m and k2m (Fig. 5). However, the majority of observed K1m
values are below 0.5 (many overlapping data at lower K1m),
and K1m and k2m are well correlated. The higher K1m and k2m
values are possibly the result of noise, as the higher values for
K1m and k2m were generally seen for the smallest ROIs used.
Moreover, the relative slow in-grow of metabolites, i.e., the
metabolite input function shows a slow increase rather than a
sharp peak, makes estimation of individual micro-parameters
less precise. Note, however, that the macro-parameter VTm is
reasonably stable across anatomical regions and subjects.
Observed improvements in fits and correlations for
models that incorporate a labeled metabolite compartment,
together with the reasonably constant VTm, suggest that
metabolites enter the brain. This is in line with a previous
assessment using multi-input spectral analysis [27]a n d
initial animal studies where labeled metabolites of [
18F]
FDDNP were injected [28]. Additional studies are, however,
needed to confirm whether this is indeed the case.
Simulation Studies
The standard 2T4k plasma input model was not a good model
for estimating the level of specific [
18F]FDDNP binding
directly (i.e., as defined by k3/k4). Firstly, although BPND bias
calculated relative to total binding potential showed good
accuracy, it only had mediocre precision. Secondly, at lower
regional delivery (=K1) levels, its bias was sensitive to the
actual value of K1. This increased sensitivity to K1 is related
to the kinetics of [
18F]FDDNP, which, for a normal level of
binding in regions with low delivery, are relatively slow.
Under those conditions, within the time frame of a scan, tracer
kinetics are best described by an irreversible compartment
model, which is illustrated by the increased preference for the
2T3k model according to the Akaike criterion.
The 2T1Mfvtm model did not provide accurate estimates of
(direct) BPND in the metabolite simulations (Figs. 8b and 9b).
Fig. 8. (continued).
Fig. 9. Bias of a indirect (and reference tissue) and b direct
BPND estimates from different compartment models for
simulated [
18F]FDDNP data generated using the metabolite
plasma input model (2T1M) with various target tissue binding
potentials. Error bars represent SD in bias.
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18F]FDDNP Studies 331Although data were simulated using the same model, BPND
was very sensitive to noise as a result of the large number of
fit parameters. However, VT estimates obtained with the
2T1Mfvtm model were less sensitive to noise and provided
highly accurate and precise VT values (Fig. 8c).
For plasma input models, more accurate and precise
results were obtained with indirect estimates of BPND (2T4k
i
and 2T1Mi
fvtm) than with their direct counterparts (2T4k and
2T1Mfvtm), especially in the case of metabolite simulations.
In most cases, these indirect methods showed lower bias
than BPSRTM
ND . This higher accuracy of 2T4k
i (in conven-
tional simulations) and 2T1Mi
fvtm (in metabolite simulations)
was, however, accompanied with lower precision compared
with BPSRTM
ND .
SRTM was better than FRTM, both in terms of bias and
COV. In addition, in the majority of the simulations, it was
preferred by the Akaike criterion. SRTM results were
comparable in conventional and metabolite simulations. If
no metabolites entered the brain, SRTM-derived BPND
showed a constant negative bias, although it was affected
by changes in delivery. On the other hand, when polar
metabolites entered the brain, SRTM showed increasing
negative bias with increasing VTm. However, clinical data
showed an overall constant VTm (Fig. 5). This indicates that
variable bias in SRTM-derived BPND due to variability in
VTm will be limited. Simulations showed that for VTm fixed
to the clinical estimated value (VTm=0.6), this bias also was
not sensitive to metabolite influx (Fig. 10b, K1m90.01,
BPND bias ∼−46%). Furthermore, the bias found in
these simulations could be related to the slope between
BPSRTM
ND versus BP2T1M i fvtm
ND (slope=2.59, Table 6; 100%×
(1/2.59)=39%) for the clinical studies, indicating a relatively
constant metabolite contribution in practice. Thus, SRTM
seems to be a useful method, irrespective whether labeled
metabolites enter the brain, provided that VTm is relatively
constant across the brain and between subjects, as actually
suggested by the clinical results.
Among SUVr methods, over the range of simulated
binding levels, only SUVr40–60 showed acceptable results,
with much better accuracy (−1%) than SRTM (−12%).
However, apart from a strong dependency on variations in
delivery, SUVr results were also highly dependent on differ-
ences in blood volume fractions with only an acceptable
accuracy for a specific time interval (SUVr60–90). In general,
SUVr results varied widely between different time intervals
which, together with the large uncertainties, indicate that this
might not be the ideal method for clinical studies.
In general, SRTM showed best overall performance,
although it showed some sensitivity to regional flow/
delivery differences. As expected, SRTM, like all other
reference tissue-based models, showed larger biases at lower
regional binding levels. Important advantages of SRTM
were its overall high precision and a relatively constant bias
in BPND even in the presence of labeled metabolites.
Although this bias was dependent on the actual value of
VTm, clinical data indicated that this was constant across the
brain and among subjects.
General Considerations
Amyloid plaques (and neurofibrillary tangles) do not behave
like neuroreceptors. They have complex structures with
multiple affinity sites for [
18F]FDDNP. In addition, it is
Fig. 10. Bias of BPND estimated with the simplified refer-
ence tissue model (SRTM) for simulated [
18F]FDDNP data
generated using the metabolite plasma input model (2T1M)
as function of a various VTm values and b various metabolite
influx rates (K1m). Error bars represent SD in bias.
332 M. Yaqub, et al.: Quantification of [
18F]FDDNP Studieslikely that access to amyloid sites will become more difficult
with increasing plaque size [30]. Consequently, use of
receptor-ligand models to assess amyloid load might provide
an increasing underestimation with increasing load. In
addition, quantification might be compromised by the
possibility of labeled metabolites entering the brain, espe-
cially since the fraction of labeled (polar) metabolites in
blood is high due to rapid metabolism of [
18F]FDDNP.
Nevertheless, [
18F]FDDNP may still be of value if a
difference between MCI and healthy controls can be
demonstrated, and it might be used to study pathological
effects as a function of disease severity/progression [8]. In
addition, at early stages, a stable receptor-ligand model is
likely to provide a reasonable quantitative estimate of the
pathological changes associated with AD and could there-
fore be an important tool in evaluating effects of therapy.
Clearly, given its relatively small specific signal, the value of
[
18F]FDDNP can only be determined by large comparative
clinical studies, such as the one by Small et al. [8]. From the
present study, it follows that such a comparison should
preferably be performed using SRTM as method of analysis,
as it showed high precision and constant bias across the brain
and among subjects even when metabolites enter the brain.
Conclusion
SRTM outperformed other models, providing BPND esti-
mates with high precision. As clinical data indicated that the
volume of distribution of labeled metabolites VTm was
constant across the brain and among subjects, bias in
SRTM-derived BPND will be constant and predictable. The
main potential drawback is its sensitivity to variations in
regional K1, although this did not appear to be a problem in
the clinical studies.
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